Verastem Oncology Strengthens Executive Leadership Team With Key Appointments; Dan Calkins Promoted To Chief Financial Officer From Vice President Of Finance
Portfolio Pulse from Benzinga Newsdesk
Verastem Oncology has announced key appointments to its executive leadership team. Dan Calkins has been promoted to Chief Financial Officer from Vice President of Finance. Mike Crowther has been appointed Chief Commercial and Business Strategy Officer, and David Mitchell has been appointed Senior Vice President, Head of Regulatory Affairs. These appointments come ahead of the potential commercial launch of avutometinib in combination with defactinib in low-grade serous ovarian cancer (LGSOC) and to support the advancement of its broader development program in RAS pathway-driven cancers.
October 26, 2023 | 8:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verastem Oncology has strengthened its executive team with key appointments. This move is expected to support the company's potential commercial launch of avutometinib in combination with defactinib in LGSOC and its broader development program in RAS pathway-driven cancers.
The strengthening of Verastem Oncology's executive team with experienced individuals in key positions is likely to have a positive impact on the company's operations and strategic direction. This could potentially lead to a positive market reaction, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100